** This website does not use cookies **

NTAG logo

NHS logo




tablets



Recommendations and Appraisals

Eye

On this page you will find our appraisal documents and recommendations sorted by BNF chapter.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the
NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary
on rdtc.rxsupp@nuth.nhs.uk


 

spacer

Title

Documents

Decision

Date

spacer

spacer

spacer

spacer

Anti-vascular endothelial growth factor therapies (bevacizumab or ranibizumab) as an adjunct to vitrectomy in diabetic retinopathy (NETAG)

Recommendation

Appraisal

Not recommended

07/07/2009

 

Bevacizumab (Avastin®) for age-related macular degeneration
(Updated)

Recommendation

Appraisal

Recommended as an option

09/09/2014

Patient letter

Updated Appraisal

 

 

Bevacizumab (Avastin®) for diabetic macular oedema (NETAG)

Recommendation

Appraisal

Not recommended

10/07/2012

Bevacizumab (Avastin®) for neovascular glaucoma secondary to central retinal vein occlusion (NETAG)

Recommendation

Appraisal

Not recommended

12/04/2011

Bevacizumab (Avastin®) or ranibizumab (Lucentis®) for macular oedema secondary to retinal vein occlusion(s)(NETAG) 

Recommendation

Appraisal

Bevacizumab (Avastin®) 1.25 mg using a ‘when required’ (PRN) regimen is recommended for management of macular oedema secondary to retinal vein occlusion

18/01/2011

Bevacizumab (Avastin®) or ranibizumab (Lucentis®) for non-AMD choriodal neovascular disease (NETAG) 

Recommendation

Appraisal

Recommends bevacizumab intravitreal injection using a ‘when required’ dose regimen for the treatment of non-AMD CNV, as described in the North East Retinal Group treatment guideline
 

08/10/2009

Treatment guidelines

High dose multivitamins and minerals for the prevention of progression of age-related macular degeneration

Recommendation

Appraisal

Not recommended

03/06/2014

Intraocular telescope by VisionCare™ for age-related macular degeneration (NETAG)
 

Recommendation

Appraisal

Not recommended

13/11/2012

Ozurdex® dexamethasone ocular implant for posterior segment uveitis (NETAG)

Recommendation

Appraisal

Recommended for uveitis in accordance with the defined treatment protocol from the
North East Retinal Group

20/03/2012

Treatment protocol

 

Sequential pharmacological therapies in the management of macular oedema secondary to retinal vein occlusion

Recommendation

Appraisal

Recommended

09/09/2014

RVO treatment pathway

 

Verteporfin (Visudyne®) with photo-dynamic therapy for chronic central serous chorioretinopathy

Recommendation

Appraisal

Not recommended

25/11/2014

 

NTAG image of tablets

spacer

       Terms and Conditions              RSS Feed              Archived Recommendations

spacer